Gui Han Lee
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Gui Han Lee has a total of 98 co-authors. Here are the top co-authors by number of shared publications:
- David Bernardo
Mucosal Immunology Lab, Instituto de Biología y Genética Molecular (IBGM, Universidad de Valladolid-CISC), Valladolid, Spain
9 shared publications - Stella C. Knight
Antigen Presentation Research Group, Imperial College London, Northwick Park and St. Mark's Campus, Harrow, UK
6 shared publications - Alan Askari
Bedfordshire Hospitals NHS Foundation Trust, Luton, UK
5 shared publications Morgan Moorghen
Department of Pathology, St Mark's Hospital, London, UK
5 shared publications- George Malietzis
Division of Surgery & Cancer, Imperial College London, St Mary’s Hospital, London, UK
4 shared publications Ailsa L. Hart
St. Mark’s Hospital, North West London Hospitals NHS Trust, Harrow, United Kingdom
3 shared publications
Latest Publications
- Open Access
- 1 January 2016
- Published by Elsevier in Cellular and Molecular Gastroenterology and Hepatology
- Vol. 2 (1) , 22-39.e5
Chemokine (C-C Motif) Receptor 2 Mediates Dendritic Cell Recruitment to the Human Colon but Is Not Responsible for Differences Observed in Dendritic Cell Subsets, Phenotype, and Function Between the Proximal and Distal Colon
- 1 January 2016
- Published by Elsevier in Cellular and Molecular Gastroenterology and Hepatology
- Vol. 2 (1) , 22-39.e5
Open AccessChemokine (C-C Motif) Receptor 2 Mediates Dendritic Cell Recruitment to the Human Colon but Is Not Responsible for Differences Observed in Dendritic Cell Subsets, Phenotype, and Function Between the Proximal and Distal Colon
- Open Access
- 1 October 2015
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 110 (10) , 1461-1471
Low-Grade Dysplasia in Ulcerative Colitis: Risk Factors for Developing High-Grade Dysplasia or Colorectal Cancer
OBJECTIVES: METHODS: RESULTS: CONCLUSIONS:
- 1 October 2015
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 110 (10) , 1461-1471
Open AccessLow-Grade Dysplasia in Ulcerative Colitis: Risk Factors for Developing High-Grade Dysplasia or Colorectal Cancer
OBJECTIVES: METHODS: RESULTS: CONCLUSIONS:
- Open Access
- 14 July 2015
- Published by Wiley in Journal of Surgical Oncology
- Vol. 112 (1) , 86-92
The prognostic significance and relationship with body composition of CCR7-positive cells in colorectal cancer
The host local immune response (LIR) to cancer is a determinant of cancer outcome. Regulation of this local response is largely achieved through chemokine synthesis from the tumor microenvironment such as C-Chemokine-Receptor-7 (CCR7). We examined the LIR measured as CCR7 expression, in colorectal cancers (CRC) and explored relationships with body composition (BC) and survival. A study of paraffin-embedded tissue specimens was carried out in 116 patients with non-metastatic CRC. CCR7 expression was determined by immunohistochemistry. Analysis of computer tomography scans was used to calculate BC parameters. Survival analyses and multivariate regression models were used. High CCR7(+) cell density within the tumor stroma and at the margin was significantly associated with increased age, the presence of lymphovascular invasion, higher tumor stage, lymph node metastasis, high Klintrup-Makinen immune score, and myosteatosis. High CCR7(+) cell density in the tumor margin was significantly associated with shorter disease-free (DFS) and overall survival (OS) (P < 0.001). This was also significantly associated with shorter survival in multivariate analysis (HR = 8.87; 95%CI [2.51-31.3]; P < 0.01 for OS and HR = 4.72; 95%CI (1.24-12.9); P = 0.02 for DFS). Our results suggest that a specific immune microenvironment may be associated with altered host's BC and tumor behavior, and that CCR7 may serve as a novel prognostic biomarker.
- 14 July 2015
- Published by Wiley in Journal of Surgical Oncology
- Vol. 112 (1) , 86-92
Open AccessThe prognostic significance and relationship with body composition of CCR7-positive cells in colorectal cancer
The host local immune response (LIR) to cancer is a determinant of cancer outcome. Regulation of this local response is largely achieved through chemokine synthesis from the tumor microenvironment such as C-Chemokine-Receptor-7 (CCR7). We examined the LIR measured as CCR7 expression, in colorectal cancers (CRC) and explored relationships with body composition (BC) and survival. A study of paraffin-embedded tissue specimens was carried out in 116 patients with non-metastatic CRC. CCR7 expression was determined by immunohistochemistry. Analysis of computer tomography scans was used to calculate BC parameters. Survival analyses and multivariate regression models were used. High CCR7(+) cell density within the tumor stroma and at the margin was significantly associated with increased age, the presence of lymphovascular invasion, higher tumor stage, lymph node metastasis, high Klintrup-Makinen immune score, and myosteatosis. High CCR7(+) cell density in the tumor margin was significantly associated with shorter disease-free (DFS) and overall survival (OS) (P < 0.001). This was also significantly associated with shorter survival in multivariate analysis (HR = 8.87; 95%CI [2.51-31.3]; P < 0.01 for OS and HR = 4.72; 95%CI (1.24-12.9); P = 0.02 for DFS). Our results suggest that a specific immune microenvironment may be associated with altered host's BC and tumor behavior, and that CCR7 may serve as a novel prognostic biomarker.
- 1 July 2015
- Published by Elsevier in Journal of Pediatric Surgery
- Vol. 50 (7) , 1241
Ileal pouch anal anastomosis in pediatric familial adenomatous polyposis: A 24-year review of operative technique and patient outcomes.
- 1 July 2015
- Published by Elsevier in Journal of Pediatric Surgery
- Vol. 50 (7) , 1241
Ileal pouch anal anastomosis in pediatric familial adenomatous polyposis: A 24-year review of operative technique and patient outcomes.
- Top Cited PapersOpen Access
- 1 July 2015
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 110 (7) , 1022-1034
Forty-Year Analysis of Colonoscopic Surveillance Program for Neoplasia in Ulcerative Colitis: An Updated Overview
Objectives: Methods: Results: Conclusions:
- 1 July 2015
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 110 (7) , 1022-1034
Top Cited PapersOpen AccessForty-Year Analysis of Colonoscopic Surveillance Program for Neoplasia in Ulcerative Colitis: An Updated Overview
Objectives: Methods: Results: Conclusions:
- Top Cited Papers
- 1 March 2015
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 41 (3) , 300-308
Is right-sided colon cancer different to left-sided colorectal cancer? – A systematic review
- 1 March 2015
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 41 (3) , 300-308
Top Cited PapersIs right-sided colon cancer different to left-sided colorectal cancer? – A systematic review
- Open Access
- 9 February 2015
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 212 (3) , 351-367
Immature myeloid cells directly contribute to skin tumor development by recruiting IL-17–producing CD4+ T cells
Evidence links chronic inflammation with cancer, but cellular mechanisms involved in this process remain unclear. We have demonstrated that in humans, inflammatory conditions that predispose to development of skin and colon tumors are associated with accumulation in tissues of CD33+S100A9+ cells, the phenotype typical for myeloid-derived suppressor cells in cancer or immature myeloid cells (IMCs) in tumor-free hosts. To identify the direct role of these cells in tumor development, we used S100A9 transgenic mice to create the conditions for topical accumulation of these cells in the skin in the absence of infection or tissue damage. These mice demonstrated accumulation of granulocytic IMCs in the skin upon topical application of 12-O-tetradecanoylphorbol-13-acetate (TPA), resulting in a dramatic increase in the formation of papillomas during epidermal carcinogenesis. The effect of IMCs on tumorigenesis was not associated with immune suppression, but with CCL4 (chemokine [C-C motif] ligand 4)-mediated recruitment of IL-17–producing CD4+ T cells. This chemokine was released by activated IMCs. Elimination of CD4+ T cells or blockade of CCL4 or IL-17 abrogated the increase in tumor formation caused by myeloid cells. Thus, this study implicates accumulation of IMCs as an initial step in facilitation of tumor formation, followed by the recruitment of CD4+ T cells.
- 9 February 2015
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 212 (3) , 351-367
Open AccessImmature myeloid cells directly contribute to skin tumor development by recruiting IL-17–producing CD4+ T cells
Evidence links chronic inflammation with cancer, but cellular mechanisms involved in this process remain unclear. We have demonstrated that in humans, inflammatory conditions that predispose to development of skin and colon tumors are associated with accumulation in tissues of CD33+S100A9+ cells, the phenotype typical for myeloid-derived suppressor cells in cancer or immature myeloid cells (IMCs) in tumor-free hosts. To identify the direct role of these cells in tumor development, we used S100A9 transgenic mice to create the conditions for topical accumulation of these cells in the skin in the absence of infection or tissue damage. These mice demonstrated accumulation of granulocytic IMCs in the skin upon topical application of 12-O-tetradecanoylphorbol-13-acetate (TPA), resulting in a dramatic increase in the formation of papillomas during epidermal carcinogenesis. The effect of IMCs on tumorigenesis was not associated with immune suppression, but with CCL4 (chemokine [C-C motif] ligand 4)-mediated recruitment of IL-17–producing CD4+ T cells. This chemokine was released by activated IMCs. Elimination of CD4+ T cells or blockade of CCL4 or IL-17 abrogated the increase in tumor formation caused by myeloid cells. Thus, this study implicates accumulation of IMCs as an initial step in facilitation of tumor formation, followed by the recruitment of CD4+ T cells.
- Open Access
- 1 January 2015
- Published by Taylor & Francis in Medical Education Online
- Vol. 20 (1) , 28453
Impact of tailored feedback in assessment of communication skills for medical students
Impact of tailored feedback in assessment of communication skills for medical students
- 1 January 2015
- Published by Taylor & Francis in Medical Education Online
- Vol. 20 (1) , 28453
Open AccessImpact of tailored feedback in assessment of communication skills for medical students
Impact of tailored feedback in assessment of communication skills for medical students
- Open Access
- 20 October 2014
- Published by Taylor & Francis in Cell Communication & Adhesion
- Vol. 22 (1) , 9-14
Prognostic Value of the Tumour-Infiltrating Dendritic Cells in Colorectal Cancer: A Systematic Review
Prognostic Value of the Tumour-Infiltrating Dendritic Cells in Colorectal Cancer: A Systematic Review. . ???aop.label???. doi: 10.3109/15419061.2015.1036859
- 20 October 2014
- Published by Taylor & Francis in Cell Communication & Adhesion
- Vol. 22 (1) , 9-14
Open AccessPrognostic Value of the Tumour-Infiltrating Dendritic Cells in Colorectal Cancer: A Systematic Review
Prognostic Value of the Tumour-Infiltrating Dendritic Cells in Colorectal Cancer: A Systematic Review. . ???aop.label???. doi: 10.3109/15419061.2015.1036859
- 27 August 2014
- Published by Bentham Science Publishers Ltd. in Current Cancer Drug Targets
- Vol. 14 (7) , 610-620
The Role of CD40 Expression in Dendritic Cells in Cancer Biology; A Systematic Review
CD40 is a co-stimulatory molecule belonging to the tumor necrosis factor superfamily and is essential in activation of dendritic cells. Dendritic cells (DCs) are antigen-presenting cells capable of initiating cytotoxic T-lymphocyte immune response against cancer cells. However, there are few studies on the characterization of DCs in cancer, specifically their expression of CD40, despite its implication in cancer immunotherapy. We reviewed available data on the expression of CD40 on DCs in various cancers, and its implications for cancer immunotherapy. A systematic review on CD40 expression on DCs in cancer was performed with reference to preferred reporting items for systematic reviews and meta-analyses (PRISMA). Studies that satisfied the inclusion and exclusion criteria were 21 out of 927. Variations in type and status of the cancers, source of DCs and methodology for detecting CD40 expression amongst the studies resulted in contrasting results. DCs generally expressed low CD40 in tumor infiltrating DCs (tiDCs), in DCs derived by in vitro culture from blood monocytes using cytokine stimulation (MoDCs) and in DCs exposed in vitro to tumor cells lines; the studies suggested that CD40 expression in DCs is impaired in cancer particularly in metastatic disease. However, DCs identified in fresh peripheral blood mononuclear cells (PBMC) expressed higher numbers of CD40 positive cells in some cancer patients, which could be due to tumor-derived factors leading to partially-stimulated DCs. The results provide evidence that some cancer patients may show partial systemic DC activation and expression of increased CD40 in response to the presence of tumor but that such activity may become abortive in the presence of factors produced by the tumor. This review has thus identified key papers on CD40 expression on DCs in various cancers and discusses the limitations and contrasting results of these studies in relation to variations in methodology. The results highlight the need for further studies on the role of CD40-CD40 ligand pathway to inform cancer treatment.
- 27 August 2014
- Published by Bentham Science Publishers Ltd. in Current Cancer Drug Targets
- Vol. 14 (7) , 610-620
The Role of CD40 Expression in Dendritic Cells in Cancer Biology; A Systematic Review
CD40 is a co-stimulatory molecule belonging to the tumor necrosis factor superfamily and is essential in activation of dendritic cells. Dendritic cells (DCs) are antigen-presenting cells capable of initiating cytotoxic T-lymphocyte immune response against cancer cells. However, there are few studies on the characterization of DCs in cancer, specifically their expression of CD40, despite its implication in cancer immunotherapy. We reviewed available data on the expression of CD40 on DCs in various cancers, and its implications for cancer immunotherapy. A systematic review on CD40 expression on DCs in cancer was performed with reference to preferred reporting items for systematic reviews and meta-analyses (PRISMA). Studies that satisfied the inclusion and exclusion criteria were 21 out of 927. Variations in type and status of the cancers, source of DCs and methodology for detecting CD40 expression amongst the studies resulted in contrasting results. DCs generally expressed low CD40 in tumor infiltrating DCs (tiDCs), in DCs derived by in vitro culture from blood monocytes using cytokine stimulation (MoDCs) and in DCs exposed in vitro to tumor cells lines; the studies suggested that CD40 expression in DCs is impaired in cancer particularly in metastatic disease. However, DCs identified in fresh peripheral blood mononuclear cells (PBMC) expressed higher numbers of CD40 positive cells in some cancer patients, which could be due to tumor-derived factors leading to partially-stimulated DCs. The results provide evidence that some cancer patients may show partial systemic DC activation and expression of increased CD40 in response to the presence of tumor but that such activity may become abortive in the presence of factors produced by the tumor. This review has thus identified key papers on CD40 expression on DCs in various cancers and discusses the limitations and contrasting results of these studies in relation to variations in methodology. The results highlight the need for further studies on the role of CD40-CD40 ligand pathway to inform cancer treatment.